Apellis Pharmaceuticals Overview
Apellis Pharmaceuticals Target Price
Analysts' 12-month price predictions for APLS.
Share Price
$41.31
Average Target Price
$80.00
93.7% upside
93.7% upside1 analysts in the last 4 months
High: $80 | Low: $80
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2024-02-05 | JefferiesAkash Tewari | $80 | 93.7% upside |  |
| 2023-01-02 | Wells FargoDerek Archila | $58 | 40.4% upside | |
| 2022-11-15 | J.P. Morgan | $79 | 91.2% upside | |
| 2022-09-12 | Wedbush | $67 | 62.2% upside | |
| 2022-09-08 | Stifel Nicolaus | $65 | 57.3% upside | |
| 2022-08-18 | Oppenheimer | $78 | 88.8% upside | |
| 2022-08-09 | Credit Suisse | $52 | 25.9% upside | |
| 2022-08-09 | Goldman Sachs | $102 | 146.9% upside | |
| 2022-08-09 | Raymond James | $113 | 173.5% upside | |
| 2022-07-20 | Citigroup | $86 | 108.2% upside | |
| 2022-06-23 | Stifel NicolausAnnabel Samimy | $60 | 45.2% upside | |
| 2022-05-24 | Goldman Sachs | $84 | 103.3% upside | |
| 2022-05-05 | Credit Suisse | $44 | 6.5% upside | |
| 2022-05-05 | Raymond James | $102 | 146.9% upside | |
| 2021-11-09 | WedbushLaura Chico | $28 |  32.2% downside | |
| 2021-11-09 | BMO CapitalMatthew Luchini | $69 | 67% upside | |
| 2021-10-01 | JefferiesChris Howerton | $74 | 79.1% upside | |
| 2021-10-01 | Cantor FitzgeraldAlethia Young | $74 | 79.1% upside | |
| 2021-09-10 | Credit SuisseTiago Fauth | $38 | 8% downside | |
| 2021-07-01 | Cowen & Co.Phil Nadeau | $70 | 69.5% upside | |